YouTube video thumbnail

Avacta (AVCT ) CEO, Alastair Smith, discusses their recent business update. He covers their two platform technologies along with their lateral flow antigen test and 2021 milestones

1.  Summary of Avacta’s two breakthrough platforms (48 seconds)
2.   Rapid lateral flow antigen tests (7mins 18secs)
3.   pre|CISION - tumour targeted chemotherapy & phase 1 trial of Pro-doxorubicin (19mins 58sec)
4.   Affimer bio/immuno-therapies (25mins 53secs)
5.   3rd party licensing initiatives (31mins 8secs)
6.   Key milestones over next 12 months (36mins 23secs)